Psoriasis, Depression, and Suicidality.
Psoriasis, Depression, and Suicidality. Skin Therapy Lett. 2017 May;22(3):1-4 Authors: Nicholas MN, Gooderham M Abstract Psoriasis is a chronic condition that affects the well-being and quality of life of patients. The disease is associated with an increased risk of depression and suicidality, which may not be fully understood by the general population. It is crucial to understand the effect this disease has on mental health and determine risk factors that may help identify patients who are susceptible to depression and suicidality. Risk factors discussed in this article include age, gender, and severity of disease in psoriasis patients. Of these, age and severity of disease are significant with a clear association of increased depression and suicidality found in patients who are younger or have more severe disease. Although there is evidence that psoriasis treatments can improve both disease and associated depression symptoms, there are high rates of undertreatment. By identifying high-risk psoriasis patients, dermatologists can aim for optimal treatment of the disease and thus help alleviate the associated psychiatric burden. PMID: 28486717 [PubMed - in process]
Conclusion: CBT as an adjunct to conventional dermatological treatments may be particularly beneficial for individuals with more severe pretreatment psychopathology in improving psoriasis severity, anxiety, and depression symptoms. CBT appears to be generally effective in improving quality of life. Greater methodological rigour is needed in future research. PMID: 31696748 [PubMed - as supplied by publisher]
ConclusionThis study provides some initial evidence on what the mechanisms of mindfulness might be.
We examined rates of depression screening among in psoriasis and AD in United States outpatients. PMID: 31648383 [PubMed - as supplied by publisher]
AbstractPsoriasis is a prevalent skin disease that impairs multiple domains of quality of life (QoL). Pruritus, a common symptom in patients with psoriasis, may directly affect sleep, but studies investigating this are limited. We investigated the relationships between pruritus and sleep in 104 in-patients with psoriasis, who underwent dermatological assessment and completed questionnaires to determine psoriasis severity, pruritus intensity, sleep quality, QoL (skin disease-specific and generic), depressive mood and anxiety. In total, 80% of patients reported pruritus, and 39% had sleep disturbances, most commonly awakenin...
Eating less processed food and more fruit, vegetables, fish and olive oil improved depression symptoms Related items fromOnMedica Psoriasis linked to raised risk of many mental health problems GPs need more time to treat complex needs Report reveals toll of living with rare diseases Mental health services face double whammy Should we recognise obesity as a disease?
CONCLUSION: RAPID3 and PSAID12 have excellent construct validity in PsA and are strongly correlated despite differing items. Contextual factors (i.e., the presence of depression and obesity) should be considered when interpreting raw scores of the RAPID3 and PSAID12. PMID: 31575704 [PubMed - as supplied by publisher]
ConclusionsThe results suggest that MBCT may be a useful adjunct therapy for those suffering from psoriasis and the associated psychological symptoms relating to the condition.
Suicidal ideation has been reported in psoriasis patients treated with brodalumab, which led to a black box warning. Is there enough evidence to establish causality, or are other factors involved?Skin Therapy Letter
AbstractBackgroundChronic inflammatory diseases such as psoriasis require treatment options that maintain efficacy and tolerability during extended treatment.ObjectiveThe aim of the study was to assess the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.MethodsPatients who completed a 12-week, phase II, dose-ranging clinical trial received brodalumab 210 mg every 2 weeks in an open-label extension study. Efficacy was assessed by static physician’s global assessment (sPGA) and psoriasis area a...
The association between psoriasis and risk of psychiatric disorders has not been thoroughly evaluated in a large longitudinal cohort of Asian population. We conducted a nationwide population-based retrospective cohort study encompassing more than 1.6 million Koreans with a 12-year follow-up period. Patients were considered in the psoriasis cohort if they had an incident diagnostic code for psoriasis and included patients were followed up until they developed any psychiatric disease. In adjusted models, psoriasis patients (n = 10,868) were at a 18% increased risk for depression (hazard ratio [HR] 1.18, 95% confidence interv...